Combination of PV-10 Immuno-chemoablation and Systemic anti-CTLA-4 Antibody Therapy in Murine Models of Melanoma

Eric A. Wachter, Savannah O. Blair, Jamie M. Singer and H. Craig Dees
Provectus Pharmaceuticals, Inc., Knoxville, TN, USA

Abstract

Bilateral Flank Tumor Model: Low Dose (PV10) + IP (B16-F10)

Bilateral Flank Tumor Model: Mid Dose (PV10) + IP (B16-F10)

Bilateral Flank Tumor Model: High Dose (PV10) + IP (B16-F10)

Discussion

Overall Survival: The survival curves for the various treatment groups are shown in this graph. The Kaplan-Meier survival analysis was performed using the GraphPad Prism software. The overall survival was calculated using the log-rank test to compare the survival curves between the treatment groups. The survival curves show a significant difference in survival between the control group and the treatment groups. The survival benefit is especially pronounced in the high-dose group, indicating a potential synergistic effect of the combination therapy.

References